Identification of Anti-Cancer Antibodies and Antigens by Massively Parallel Sequencing of Tumor Infiltrating Lymphocytes

摘要

The development of new cancer therapies will greatly benefit from the discovery of novel cancer-associated molecular targets. Interrogating patient immune responses to find naturally recognized targets is an attractive strategy, yet problematic for several reasons: the number of tumor infiltrating lymphocytes (TILs) in a tumor can be large and only a tiny minority (<1%) of B- and T-cells may carry tumor-specific receptors; the surface marker phenotypes of TILs are unpredictable; and TIL receptor analysis ideally requires a single cell-based approach to recover natively paired receptor chains.